Posts

28bio Launches CNS-3D Myelinated Organoids to Predict Therapeutic Efficacy

on

GSK strikes RNA-based neuro and kidney disease collaboration with CAMP4 Therapeutics

on

Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer's Disease at CTAD Conference

on

NewcelX Appoints Jeremy Shefner to Scientific Advisory Board

on

VectorY Strikes $1.2B Option and License Pact with Shape Therapeutics for Brain-Penetrant Gene Therapy Delivery

on

Sanofi Acquires Vigil Neuroscience for $470 Million, Bolstering Alzheimer's Drug Pipeline

on

FDA Delays Decision on Biohaven's Troriluzole for Rare Disease, Plans Advisory Committee Review

on

Azafaros Raises €132M in Series B to Fund Phase 3 Trials for Brain-Penetrant Drug

on

GSKs newest neuro pact is with ABL Bio, a Sanofi-partnered South Korean biotech

on

TRIMTECH Therapeutics raises $31M seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseases

on